Literature DB >> 6971388

Serological findings in patients with "ANA-negative" systemic lupus erythematosus.

P J Maddison, T T Provost, M Reichlin.   

Abstract

Serological studies were performed on sera from 66 patients with the clinical picture of systemic lupus erythematosus (SLE). These sera failed to give a positive antinuclear antibody test when tested on cryostat sections of mouse liver and thus these patients' sera appear to be ANA negative. Precipitating antibodies to the cytoplasmic antigen Ro were found in 41 cases and of the remaining 25 sera, 18 were found to have antibodies to single stranded DNA detectable by radioimmunoassay. Thus, 50 of the 66 patients exhibited serological findings which are commonly found in ANA positive SLE patients. Studies with KB cells as immunofluorescent substrate revealed that 66% of these sera were positive for nuclear staining demonstrating that at least part of the failure of these sera to stain mouse liver is due to antigenic deficiency of this substrate. The clinical picture of these patients was dominated by a severe photosensitive dermatitis but more than half of the patients had widespread multisystem disease. As a group these patients had a low frequency of nephritis and neuropsychiatric disease. Detection of these antibodies relates these patients serologically to other SLE patients and suggests that they are best perceived as part of the clinical spectrum of SLE.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6971388     DOI: 10.1097/00005792-198103000-00002

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  59 in total

1.  An unusual case of ANA negative systemic lupus erythematosus presented with vasculitis, long-standing serositis and full-house nephropathy.

Authors:  Aysun Caltik; Gülay Demircin; Mehmet Bülbül; Ozlem Erdogan; Sare G Akyüz; Nilüfer Arda
Journal:  Rheumatol Int       Date:  2010-06-08       Impact factor: 2.631

Review 2.  Significance of the Ro antigen system.

Authors:  M Reichlin
Journal:  J Clin Immunol       Date:  1986-09       Impact factor: 8.317

Review 3.  Utility of serologic testing in the diagnosis of noninfectious pulmonary disorders.

Authors:  R H White; J A Golden
Journal:  Clin Rev Allergy       Date:  1990 Summer-Fall

4.  The genetic basis of Ro and La antibody formation in systemic lupus erythematosus. Results of a multicenter study. The SLE Study Group.

Authors:  K Hartung; H Ehrfeld; H J Lakomek; R Coldewey; B Lang; F Krapf; R Müller; D Schendel; H Deicher; H P Seelig
Journal:  Rheumatol Int       Date:  1992       Impact factor: 2.631

5.  The many faces of lupus.

Authors:  H El-Gabalawy
Journal:  Can Fam Physician       Date:  1990-05       Impact factor: 3.275

6.  Multiple tendon ruptures in a patient affected by anti-SSA/Ro antibody positive rheumatoid arthritis.

Authors:  P Caramaschi; D Biasi; A Carletto; T Manzo; M Randon; M L Pacor; L M Bambara
Journal:  Clin Rheumatol       Date:  1997-11       Impact factor: 2.980

7.  Molecular cloning, expression, and chromosome 19 localization of a human Ro/SS-A autoantigen.

Authors:  D P McCauliffe; F A Lux; T S Lieu; I Sanz; J Hanke; M M Newkirk; L L Bachinski; Y Itoh; M J Siciliano; M Reichlin
Journal:  J Clin Invest       Date:  1990-05       Impact factor: 14.808

8.  Use of cultured epithelial cells, including keratinocytes, for the detection of antinuclear antibodies.

Authors:  I Leigh; F Wojnarowska; S Burge; B Bhogal; T Zhu
Journal:  Ann Rheum Dis       Date:  1987-12       Impact factor: 19.103

9.  Severe Raynaud's phenomenon in a patient with antinuclear antibody-negative systemic lupus erythematosus.

Authors:  C J Maxwell; E Potter; J Townsend
Journal:  J Natl Med Assoc       Date:  1988-05       Impact factor: 1.798

10.  Hypersensitivity to molybdenum as a possible trigger of ANA-negative systemic lupus erythematosus.

Authors:  M Federmann; B Morell; G Graetz; M Wyss; P Elsner; R von Thiessen; B Wüthrich; D Grob
Journal:  Ann Rheum Dis       Date:  1994-06       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.